Is travel-time to a specialist centre a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection?

Social Science and Medicine

Volumn 75, Issue 1, 2012, Pages 240-247

  Astell Burt, Thomas ^a,b   Flowerdew, Robin ^b   Boyle, Paul ^b   Dillon, John ^c  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Attendance; Geographic information systems (GIS); Hepatitis C Virus (HCV); Referral; Specialist centre; Travel time; UK, Scotland

Indexed keywords

DISEASE TREATMENT; GIS; HEALTH SERVICES; HEPATITIS; HOSPITAL SECTOR; LOGIT ANALYSIS; REGRESSION ANALYSIS; RISK FACTOR; TRAVEL TIME;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PATIENT ATTITUDE; PATIENT PARTICIPATION; PATIENT REFERRAL; RISK FACTOR; TRAVEL; TRAVEL TIME;

ADULT; APPOINTMENTS AND SCHEDULES; CONFIDENCE INTERVALS; DATABASES, FACTUAL; FEMALE; GEOGRAPHIC INFORMATION SYSTEMS; GEOGRAPHY; GREAT BRITAIN; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HEPATITIS C; HUMANS; LOGISTIC MODELS; MALE; MEDICINE; ODDS RATIO; PATIENT SATISFACTION; REFERRAL AND CONSULTATION; RISK FACTORS; TIME; TRAVEL;

SCOTLAND; TAYSIDE; UNITED KINGDOM;

HEPATITIS C VIRUS;

EID: 84860698283     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2012.02.046     Document Type: Article

References (57)

1. Alter M.J. Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology 2007, 13:2436-2441.
2. Astell-Burt T., Flowerdew R., Boyle P.J., Dillon J.F. Does geographic access to primary healthcare influence the detection of hepatitis C?. Social Science & Medicine 2011, 72:1472-1481.
3. Athas W.F., Adams-Cameron M., Hunt W.C., Amir-Fazli A., Key C.R. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. Journal of the National Cancer Institute 2000, 2:269-271.
4. Beardsley K., Wish E.D., Fitzelle D.B., O'Grady K., Arria A.M. Distance traveled to outpatient drug treatment and client retention. Journal of Substance Abuse Treatment 2003, 25:279-285.
5. Bini E.J., Brau N., Currie S., Shen H., Anand B.S., Hu K.Q., et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 US veterans with chronic hepatitis C virus infection. The American Journal of Gastroenterology 2005, 100:1772-1779.
6. Boyle P.J., Kudlac H., Williams A.J. Geographical variation in the referral of patients with chronic end stage renal failure for renal replacement therapy. Quarterly Journal of Medicine 1996, 89:151-157.
7. Butt A.A., Justice A.C., Skanderson M., Rigsby M.O., Good C.B., Kwoh C.K. Rate and predictors of treatment prescription for hepatitis C. British Medical Journal 2007, 56:385-389.
8. Butt A.A., Wagener M., Shakil A.O., Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. Journal of Viral Hepatitis 2005, 12:81-85.
9. Carstairs V., Morris R. Deprivation and mortality: an alternative to social class?. Journal of Public Health 1989, 11:210-219.
10. Cordoba J., Flavia M., Jacas C., Sauleda S., Esteban J.I., Vargas V., et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. Journal of Hepatology 2003, 39:231-238.
11. d'Souza R.F.C., Glynn M.J., Alstead E., Osonayo C., Foster G.R. Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign. Quarterly Journal of Medicine 2004, 97:331-336.
12. Davis M., Rhodes T. Beyond prevention? Injecting drug user narratives about hepatitis C. International Journal of Drug Policy 2004, 15:123-131.
13. Davis M., Rhodes T., Martin A. Preventing hepatitis C:'Common sense','the bug'and other perspectives from the risk narratives of people who inject drugs. Social Science & Medicine 2004, 59:1807-1818.
14. Dillon J.F. Hepatitis C: what is the best treatment. Journal of Viral Hepatology 2004, 11:23-27.
15. Esteban J.I., Sauleda S., Quer J. The changing epidemiology of hepatitis C virus infection in Europe. Journal of Hepatology 2008, 48(1):148-162.
16. Exeter D., Flowerdew R., Boyle P.J. Policy implications of pockets of deprivation in Scotland. Innovations in GIS 10: GIS and evidence-based Policy making 2008, 95-112. Taylor and Francis, London. S. Wise, M. Craglia (Eds.).
17. Farmer J., Iversen L., Campbell N.C., Guest C., Chesson R., Deans G., et al. Rural/urban differences in accounts of patients' initial decisions to consult primary care. Health & Place 2006, 12:210-221.
18. Farmer J., Lauder W., Richards H., Sharkey S. Dr John has gone: assessing health professionals' contribution to remote rural community sustainability in the UK. Social Science & Medicine 2003, 57:673-686.
19. Field K.S., Briggs D.J. Socio-economic and locational determinants of accessibility and utilization of primary health-care. Health & Social Care in the Community 2001, 9:294-308.
20. Fortney J.C., Booth B.M., Blow F.C., Bunn J.Y., Cook C.A.L. The effects of travel barriers and age on the utilization of alcoholism treatment aftercare. The American Journal of Drug and Alcohol Abuse 1995, 21:391-406.
21. Fortney J., Rost K., Zhang M., Warren J. The impact of geographic accessibility on the intensity and quality of depression treatment. Medical Care 1999, 37:884-893.
22. Fraenkel L., McGraw S., Wongcharatrawee S., Garcia-Tsao G. Patients' experiences related to anti-viral treatment for hepatitis C. Patient Education and Counselling 2006, 62:148-155.
23. Giacosa A., Hill M.J. Hepatitis C virus and hepatocellular carcinoma. European Journal of Cancer Prevention 1996, 5:423-424.
24. Hallinan R., Byrne A., Agho K., Dore G.J. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug and Alcohol Dependence 2007, 88:49-53.
25. Haynes R., Jones A.P., Sauerzapf V., Zhao H. Validation of travel-times to hospital estimated by GIS. International Journal of Health Geographics 2006, 5:40.
26. Health Protection Scotland Surveillance of known hepatitis C antibody positive cases in Scotland: Results to 31 December 2007 2008.
27. Hutchinson S.J., Roy K.M., Wadd S., Bird S.M., Taylor A., Anderson E., et al. Hepatitis C virus infection in Scotland: epidemiological review and public health challenges. Scottish Medical Journal 2006, 51:8-15.
28. Jones A.P., Haynes R., Sauerzapf V., Crawford S.M., Zhao H., Forman D. Travel-time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. European Journal of Cancer 2008, 44:992-999.
29. Kahende J.W., Adhikari B., Maurice E., Rock V., Malach A. Disparities in health care utilization by smoking status - NHANES 1999-2004. International Journal of Environmental Research and Public Health 2009, 6:1095-1106.
30. Lieb K., Engelbrecht M.A., Gut O., Fiebich B.L., Bauer J., Janssen G., et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNa): results from a prospective study. European Psychiatry 2006, 21:204-210.
31. Martin D. Geography for the 2001 census in England and Wales. Population Trends 2002, 108:7-15.
32. Meden T., St.John-Larkin C., Hermes D., Sommerschield S. Relationship between travel distance and utilization of breast cancer treatment in rural Northern Michigan. Journal of the American Medical Association 2002, 287:111.
33. Mohsen A.H., Group T.H.S. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001, 48:707-713.
34. Munoz-Plaza C.E., Strauss S., Astone-Twerell J., Jarlais D.D., Gwadz M., Hagan H., et al. Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the US. International Journal of Drug Policy 2008, 19:71-78.
35. Nattinger A.B., Kneusel R.T., Hoffmann R.G., Gilligan M.A. Relationship of distance from a radiotherapy facility and initial breast cancer treatment. Journal of the National Cancer Institute 2001, 93:1344-1346.
36. O'Donnell C.A. Variation in GP referral rates: what can we learn from the literature?. Family Practice 2000, 17:462-471.
37. Ordnance Survey OS MasterMap topography layer user guide 2008.
38. Parkes J., Roderick P., Bennett-Lloyd B., Rosenburg W. Variation in Hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom. BMC Public Health 2006, 6.
39. Paterson B.L., Backmund M., Hirsch G., Yim C. The depiction of stigmatization in research about hepatitis C. International Journal of Drug Policy 2007, 18:364-373.
40. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatolology 2006, 45:529-538.
41. Raebel M.A., Malone D.C., Conner D.A., Xu S., Porter J.A., Lanty F.A. Health services use and health care costs of obese and nonobese individuals. Archives of Internal Medicine 2004, 164:2135-2140.
42. Schmitt S.K., Phibbs C.S., Piette J.D. The influence of distance on utilization of outpatient mental health aftercare following inpatient substance abuse treatment. Addictive Behaviors 2003, 28:1183-1192.
43. Scottish Executive Urban rural classification 2005-2006 2006.
44. Scottish Government Hepatitis C action plan for Scotland phase II: May 2008-March 2011 2008, (Edinburgh).
45. Scottish Intercollegiate Guidelines Network Management of hepatitis C: A national clinical guideline 2006, (Edinburgh).
46. Shehab T.M., Sonnad S.S., Lok A.S.F. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. Journal of Viral Hepatitis 2001, 8:377-383.
47. Steinke D.T., Weston T.L., Morris A.D., MacDonald T.M., Dillon J.F. Epidemiology and economic burden of viral hepatitis: an observational population based study. Gut 2002, 50:100-105.
48. Steinke D.T., Weston T.L., Morris A.D., MacDonald T.M., Dillon J.F. The epidemiology of liver disease in Tayside database: a population-based record-linkage study. Journal of Biomedical Informatics 2002, 35:186-193.
49. Stoové M.A., Gifford S.M., Dore G.J. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug and Alcohol Dependence 2005, 77:81-86.
50. Sturm R. The effects of obesity, smoking, and drinking on medical problems and costs. Health Affairs 2002, 21:245-253.
51. Tait J.M., McIntyre P.G., McLeod S., Nathwani D., Dillon J.F. The impact of a managed care network on attendance, follow-up and treatment at a hepatitis C specialist centre. Journal of Viral Hepatitis 2010, 17:698-704.
52. Temple-Smith M., Stoove M., Smith A., O'Brien M.L., Mitchell D., Banwell C., et al. Gender differences in seeking care for hepatitis C in Australia. Journal of Substance Use 2007, 12:59-70.
53. UCLA Analyzing correlated (clustered) data 2008, Academic Technology Services SCG, Accessed 08.05.11. http://www.ats.ucla.edu/stat/stata/library/cpsu.htm.
54. Walley A.Y., White M.C., Kushel M.B., Song Y.S., Tulsky J.P. Knowledge of and interest in hepatitis C treatment at a methadone clinic. Journal of Substance Abuse Treatment 2005, 28:181-187.
55. Wang F., McDonald T., Reffitt B., Edington D.W. BMI, physical activity, and health care utilization/costs among medicare retirees. Obesity Research 2005, 13:1450-1457.
56. Williams R.L. A note on robust variance estimation for cluster-correlated data. Biometrics 2000, 56:645-646.
57. Zola I.K. Pathways to the doctor-from person to patient. Social Science & Medicine 1973, 7:677-689.